NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept

NEW YORK, April 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Johnson & Johnson Analyst Notes 

On April 1, 2014, Janssen Research & Development, LLC (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has submitted a New Drug Application (NDA) to the FDA, seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir (PREZISTA) with cobicistat. "Darunavir is the most prescribed HIV protease inhibitor in the United States1 and we are excited to be taking this important step in our efforts to offer it with an alternative boosting agent in a fixed-dose combination tablet," said Johan van Hoof, M.D., Therapeutic Area Head of Infectious Diseases and Vaccines at Janssen. "This filing demonstrates our ongoing commitment to develop new HIV treatment options and fixed-dose treatment regimens for those living with the disease." The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.AnalystsReview.com/04072014/JNJ/report.pdf

Pfizer Inc. Analyst Notes 

On March 28, 2014, Pfizer Inc. (Pfizer) announced that the FDA has approved over-the-counter Nexium 24HR (esomeprazole 20mg). According to the Company, the approval marks a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years. "Switching medicines, whenever appropriate, from prescription to non-prescription status improves access, empowers consumers to care for their own health and is an important strategy for Pfizer," said Paul Sturman, President of Pfizer Consumer Healthcare. "The FDA approval of Nexium 24HR is a significant milestone in executing against our plan." The Company said that it is working closely with AstraZeneca and retail partners to make Nexium® 24HR available to consumers in the U.S., and to follow in other markets in Europe in 2014. The full analyst notes on Pfizer Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/PFE/report.pdf

Merck & Co., Inc. Analyst Notes 

On March 27, 2014, Merck & Co., Inc. (Merck) announced the appointment of Robert M. Davis as the Company's Executive Vice President and CFO, effective April 23, 2014. Succeeding Peter N. Kellogg, Davis will be responsible for overseeing corporate strategy and corporate business development. "Rob's broad, global business and healthcare experience, which encompasses commercial, R&D, quality, regulatory, manufacturing and supply chain, will be an asset to us in implementing a significantly streamlined, more flexible cost structure and operating model, while enabling us to focus on our highest-potential growth opportunities," said Kenneth C. Frazier, Chairman and CEO, Merck. The full analyst notes on Merck & Co., Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/MRK/report.pdf

GlaxoSmithKline plc Analyst Notes 

On April 2, 2014, GlaxoSmithKline plc (GSK) announced its decision to stop the MAGRIT trial, a Phase III trial of the Company's MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer (NSCLC) patients. The Company established that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment, and thereby decided to cease the trial. "While we are extremely disappointed to learn that this trial did not have a positive outcome for the patients who participated in this trial, we are very grateful to its participants. We hope that the data generated in this trial will advance our understanding of the science of immunotherapeutics, and ultimately towards development of new therapies," said Vincent Brichard, Senior Vice President and Head of Immunotherapeutics at GSK Vaccines. The full analyst notes on GlaxoSmithKline plc are available to download free of charge at:

http://www.AnalystsReview.com/04072014/GSK/report.pdf

Intercept Pharmaceuticals, Inc. Analyst Notes 

On April 1, 2014, Intercept Pharmaceuticals, Inc. (Intercept) announced that it has commenced an underwritten public offering of 1.0 million shares of its common stock. The Company informed that 0.6 million of the shares in the offering are to be sold by Intercept, and 0.4 million are to be sold by certain institutional selling stockholders. In addition, the Company informed that the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock on the same terms and conditions. The full analyst notes on Intercept Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/ICPT/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED